Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications

Broer, Simone L.; Broekmans, Frank J.; Laven, Joop S.E.; Fauser, Bart C.J.M.

doi:10.1093/humupd/dmu020

Cited by 517 publications

(371 citation statements)

References 136 publications

Supporting

Mentioning

352

Contrasting

Unclassified

Order By: Relevance

“…However, the hesitance to fully adopt AMH into clinical practice demonstrated by our study may have a historical basis based on the development of the AMH assays integrated into clinical use [27]. Confounding the clinical use and study of AMH from 2002 to 2010 was the availability of different commercial assays, which resulted in substantially different quantitative values [28,29]. Prior to 2011, the two different tests available were the Diagnostic Systems Lab (DSL) and the Immunotech (IOT) AMH assays.…”

Section: Discussionmentioning

confidence: 96%

“…The use of two different assays created challenges to the readership of the infertility literature in applying the findings from the studies. One challenge has been that the IOT assays produced AMH concentrations up to 40 % higher than DSL, making interpretation of the absolute values difficult [28,30]. Studies that produced cut-off values and nomograms must be scrutinized for the assay used prior to applying the information, regardless of how compelling the data appears, to the reader's own clinical situation [1,31].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide

Tobler

Shoham

Christianson

et al. 2015

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The aim of this study is to assess how anti-mullerian hormone (AMH) is used worldwide to test ovarian reserve and guide in vitro fertilization (IVF) cycle management. Methods An internet-based survey was sent electronically to registered IVF providers within the IVF-Worldwide.com network. This survey consisted of nine questions which assessed the clinics' use of AMH. The questionnaire was completed online through the IVF-Worldwide.com website, and quality assurance tools were used to verify that only one survey was completed per clinical IVF center. Results are reported as the proportion of IVF cycles represented by a particular answer choice. Results Survey responses were completed from 796 globally distributed IVF clinics, representing 593,200 IVF cycles worldwide. Sixty percent of the respondent-IVF cycles reported to use AMH as a first line test, and 54 % reported it as the best test for evaluating ovarian reserve. Eighty-nine percent reported that AMH results were extremely relevant or relevant to clinical practice. However in contrast, for predicting live birth rate, 81 % reported age as the best predictor. Conclusions AMH is currently considered a first line test for evaluating ovarian reserve and is considered relevant to clinical practice by the majority of IVF providers.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide

Tobler

Shoham

Christianson

et al. 2015

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…age, and become undetectable approximately 5 years before menopause, the time when the pool of primordial follicles is considered exhausted [51]. At each specific age, individual AMH serum concentration reflects the size of the antral follicle pool, representing the quantity of the remaining primordial follicles.…”

Section: Discussionmentioning

confidence: 99%

Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram

Barnabei¹,

Strigari

Marchetti

et al. 2015

The Oncologist

View full text Add to dashboard Cite

Background. The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-Müllerian hormone (AMH) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated AMH and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in breast cancer patients. Materials and Methods. To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms "amenorrhea/chemically induced," "ovarian reserve," "anti-Mullerian hormone/blood," and "breast neoplasms/drug therapy." Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC)

show abstract

“…Recent studies demonstrated that AMH is one of the most reliable predictor of the ovarian reserve and ovarian response to stimulation in assisted reproductive technologies (ART) [2][3][4][5]. AMH is also recognized as a good indicator for potential fertility.…”

Section: Introductionmentioning

confidence: 99%

Age-Related Distribution of Basal Anti-Mullerian Hormone Levels in a Population of Infertile Women

Özcan¹,

Fıçıcıoğlu²,

Yeşiladalı³

et al. 2016

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetAmaç: Mevcut araştırmada kadınlarda serum Anti-Müllerian Hormon (AMH) ölçümlerinin yaşa özgü referans değerlerini belirlemek, yaşa özgü beklenen değerlerle ilgili bir referans değeri oluşturmak ve çocuk sahibi olmak amacıy-la infertilite polikliniğine başvuran doğurgan yaştaki Türk kadınlarının bazal serum AMH seviyelerinin dağılımını analiz etmeyi amaçladık. Gereç ve Yön-tem: Türkiye' deki tek bir infertilite merkezine 12 aylık period içinde başvuran 409 kadının siklusun 2-3. gününde prospektif olarak toplanan AMH ölçümleri-nin retrospektif analizi yapılmıştır. Bulgular: Serum AMH konsantrasyonu yaş-la birlikte azalma göstermiştir. Yaş ortalaması 34.04±5.39, serum AMH konsantrasyon ortalaması 1.77±1.82 idi. AMH seviyeleri 20-24, 25-29, 30-34, 35-39, ve >40 yaş gruplarına göre incelendi. Ortanca AMH değerleri belirtilen yaşlara göre sırası ile 2.16 ng/ml, 2.15 ng/ml, 1.71 ng/ml, 0.80 ng/ml ve 0.47 ng/ml'dir. Tartışma: Çalışmada sunulan mevcut veriler Türk infertile kadınlar-da serum AMH konsantrasyonu için bir çerçeve oluşturacaktır. Anahtar KelimelerAnti-Müllerian Hormon; Reprodüktif Yaş; Yaşa Özgü Değerler Concentrations of serum AMH were shown to decrease with advancing age of the female partner. The mean age of the women was 34.04±5.39 years and the mean AMH level of the women was 1.77±1.82. The AMH levels were grouped according to age as follows: 20-24, 25-29, 30-34,35-39, and >40 years. The median AMH values were 2.16 ng/ml, 2.15 ng/ml, 1.71 ng/ml, 0.80 ng/ml, and 0.47 ng/ml, respectively according to the age groups. Discussion:The present data provide a framework for age-specific serum AMH levels in a Turkish population of infertile women.

show abstract

Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications

Cited by 517 publications

References 136 publications

Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide

Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide

Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram

Age-Related Distribution of Basal Anti-Mullerian Hormone Levels in a Population of Infertile Women

Contact Info

Product

Resources

About